Turning Point Therapeutics TPTX 深 沪
等待开盘 11-06 09:30:00 美东时间
76.01
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 76.01
- 总市值 380.61万
- 52周最高 82.20
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 23.77
- 委 比 0.00%
- 总股本 5.01万
- 历史最高 141.30
- 量 比 0
- 振 幅 0.00%
- 历史最低 23.77
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics
Processa Pharmaceuticals announced FDA clearance for a Phase 2 study of VT-7208 in chronic spontaneous urticaria (CSU), with additional Phase 2 studies planned for food allergy and relapsing multiple sclerosis. The company expanded its pipeline through a collaboration with Generian Pharmaceuticals for a novel neonatal Fc receptor antagonist program. Sheila Gujrathi, M.D., was appointed Executive Chair of the Board of Directors, and the company ex...
10-29 12:00
华裔女科学家创办的BlossomHill上市：市值6.7亿美元 路演PPT曝光
雷递网 雷建平 9月5日 创新药企BlossomHill Therapeutics(股票代码：“BLSM”）已于8月初在美国纳斯达克上市，并在9月初在美国纳斯达...
09-05 11:01
再鼎医药与Turning Point Therapeutics联手攻克耐药难题
再鼎医药宣布，奥凯乐（瑞普替尼）获中国NMPA批准治疗ROS1阳性非小细胞肺癌。FDA也已批准其用于相同适应证，并给予多项突破性治疗认定及快速通道资格。再鼎医药...
2024-05-13 15:27
Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs
Dr. Levy brings more than 25 years of biopharma industry experience, including ...
2023-07-20 20:00
2023科技股能否反弹？华尔街“神预言”分析师：继续做空科技，做多医疗
随着美国通胀降温，部分机构开始看好2023年科技股表现；但有分析师“泼冷水”，阐述了2023年科技股将继续低迷的理由，去年其投资组合表现远超标普500；该分析师给出详细投资策略>>
2023-01-13 22:38
Turning Point Therapeutics (NASDAQ:TPTX) Announces Quarterly Earnings Results
Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) announced its quarterly e...
2022-08-09 20:52
